Milnacipran Micro Labs (Milnacipran Hydrochloride)

Milnacipran, the active ingredient in Milnacipran Micro Labs, is a serotonin‑norepinephrine reuptake inhibitor presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder and for managing pain associated with fibromyalgia in adult patients.

GNH USA supplies Milnacipran Micro Labs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under GMP conditions.

Milnacipran is an SNRI that modulates neurotransmitter activity in mood and pain pathways. - Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Fibromyalgia: alleviates chronic widespread pain and improves functional status in adults.

Milnacipran may be associated with several adverse reactions, ranging from frequent to rare.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Dry mouth: reduced salivation. - Insomnia: difficulty initiating or maintaining sleep. - Constipation: reduced bowel movements. - Increased sweating: hyperhidrosis.

Serious or Rare Side Effects: - Hypertension: elevated blood pressure requiring monitoring. - Tachycardia: rapid heart rate episodes. - Hepatotoxicity: abnormal liver function tests. - Serotonin syndrome: signs of excess serotonergic activity. - Severe allergic reaction: rash, angioedema, or anaphylaxis.

When prescribing Milnacipran, clinicians should consider several precautionary measures to ensure patient safety. - Assess cardiovascular status: monitor blood pressure and heart rate before and during therapy. - Evaluate hepatic function: avoid use in patients with severe liver impairment. - Review psychiatric history: use cautiously in patients with bipolar disorder or suicidal ideation. - Consider drug interactions: avoid concomitant use with MAO inhibitors or other serotonergic agents. - Monitor for serotonin syndrome: watch for agitation, hyperreflexia, or fever. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Milnacipran can interact with several medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Other serotonergic antidepressants (e.g., SSRIs, SNRIs): increased risk of serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise Milnacipran plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce drug exposure. - Antihypertensive agents: potential additive blood pressure‑lowering effect. - NSAIDs or anticoagulants: heightened risk of bleeding.